TRANSTHERA's core product announced clinical data at ASCO GI

AASTOCKS
2026.01.12 00:50

TRANSTHERA-B (02617.HK) announced its Phase II clinical data on the treatment of advanced cholangiocarcinoma (CCA) patients with its core product, Tiengotine, at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).

The study shows that FGFR inhibitors have an established role in treating cholangiocarcinoma with FGFR2 mutations. Tiengotine, as a novel FGFR inhibitor, has demonstrated promising activity in overcoming acquired resistance to previous FGFR inhibitors. This report presents an analysis of circulating tumor DNA (ctDNA) biomarkers, evaluating the efficacy of Tiengotine in treating CCA patients with FGFR2 fusions and primary resistance to FGFR inhibitors, FGFR2 fusions with acquired resistance to FGFR inhibitors, as well as other FGFR mutations or wild-type FGFR.

The report assessed genomic variations in patients' ctDNA and conducted correlation analyses of efficacy based on ctDNA mutation status and patient subgroups. These results support further investigation in the ongoing Phase III clinical trial through expanded biomarker sampling

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.